Skip to Content

Accolate (zafirlukast) Disease Interactions

There is 1 disease interaction with Accolate (zafirlukast):

Major

Zafirlukast (Includes Accolate) ↔ Liver Disease

Severe Potential Hazard, High plausibility

Applies to: Liver Disease

The use of zafirlukast may be associated with elevations of one or more liver enzymes as well as life-threatening hepatic failure. Cases of liver injury without other attributable cause have been reported from postmarketing surveillance of patients treated with the recommended dosage of zafirlukast (40 mg/day). Although most cases have been reversible following drug discontinuation, fulminant hepatitis and progression to hepatic failure, liver transplantation, and death have rarely been reported. In patients with hepatic cirrhosis, serum zafirlukast concentrations may be 50% to 60% higher than in normal patients. Zafirlukast is contraindicated in patients with hepatic impairment including hepatic cirrhosis. Periodic serum transaminase testing is recommended to enable early detection of drug-induced hepatic injury. Patients should be advised to contact their physician immediately if they experience signs or symptoms of liver dysfunction (e.g., right upper quadrant abdominal pain, nausea, fatigue, lethargy, pruritus, jaundice, flu-like symptoms, anorexia, and enlarged liver). Zafirlukast should be discontinued, and liver function tests performed immediately if hepatic injury is suspected. The drug should not be resumed if hepatic injury is confirmed. Patients in whom zafirlukast was withdrawn because of hepatic injury where no other attributable cause is identified should not be re-exposed to zafirlukast.

References

  1. Kelloway JS "Zafirlukast: the first leukotriente-receptor antagonist approved for the treatment of asthma." Ann Pharmacother 31 (1997): 1012-21
  2. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ "Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast." Ann Intern Med 133 (2000): 964-8
  3. "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.
  4. Spector SL "Leukotriene inhibitors and antagonists in asthma." Ann Allergy Asthma Immunol 75 (1995): 463-70,473-4
View all 4 references

Accolate (zafirlukast) drug Interactions

There are 288 drug interactions with Accolate (zafirlukast)

Accolate (zafirlukast) alcohol/food Interactions

There is 1 alcohol/food interaction with Accolate (zafirlukast)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide